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Aptamer-enabled uptake of small molecule ligands
Abstract
The relative ease of isolating aptamers with high specificity for target molecules suggests that molecular
recognition may be common in the folds of natural RNAs. We show here that, when expressed in cells,
aptamers can increase the intracellular concentrations of their small molecule ligands. We have named these
aptamers as DRAGINs (Drug Binding Aptamers for Growing Intracellular Numbers). The DRAGIN
property, assessed here by the ability to enhance the toxicity of their ligands, was found for some, but not all,
aminoglycoside aptamers. One aptamer protected cells against killing by its ligand. Another aptamer
promoted killing as a singlemer and protected against killing as a tandemer. Based on a mathematical model,
cell protection vs. killing is proposed as governed by aptamer affinity and access to the inner surface of the cell
membrane, with the latter being a critical determinant. With RNA molecules proposed as the earliest
functional polymers to drive the evolution of life, we suggest that RNA aptamer-like structures present in
primitive cells might have selectively concentrated precursors for polymer synthesis. Riboswitches may be the
evolved forms of these ancient aptamer-like “nutrient procurers”. Aptamers with DRAGIN capability in the
modern world could be applied for imaging cells, in synthetic cell constructs, or to draw drugs into cells to
make “undruggable” targets accessible to small molecule inhibitors.
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Aptamer-enabled uptake of small 
molecule ligands
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Robert R. Feldges2, Shambhavi Shubham1,2,6, Lee Bendickson1,2, Howard A. Levine1 & 
Marit Nilsen-Hamilton1,2,3
The relative ease of isolating aptamers with high specificity for target molecules suggests that 
molecular recognition may be common in the folds of natural RNAs. We show here that, when 
expressed in cells, aptamers can increase the intracellular concentrations of their small molecule 
ligands. We have named these aptamers as DRAGINs (Drug Binding Aptamers for Growing Intracellular 
Numbers). The DRAGIN property, assessed here by the ability to enhance the toxicity of their ligands, 
was found for some, but not all, aminoglycoside aptamers. One aptamer protected cells against 
killing by its ligand. Another aptamer promoted killing as a singlemer and protected against killing 
as a tandemer. Based on a mathematical model, cell protection vs. killing is proposed as governed by 
aptamer affinity and access to the inner surface of the cell membrane, with the latter being a critical 
determinant. With RNA molecules proposed as the earliest functional polymers to drive the evolution 
of life, we suggest that RNA aptamer-like structures present in primitive cells might have selectively 
concentrated precursors for polymer synthesis. Riboswitches may be the evolved forms of these ancient 
aptamer-like “nutrient procurers”. Aptamers with DRAGIN capability in the modern world could be 
applied for imaging cells, in synthetic cell constructs, or to draw drugs into cells to make “undruggable” 
targets accessible to small molecule inhibitors.
Controlling the entrance and exit of small molecules through the cell membrane is critical to cell survival. In 
modern cells, transmembrane protein transporters promote the entry of essential nutrients for cell prolifera-
tion. However, protein transporters were not available to early forms of life that, once surrounded by a hydro-
phobic membrane, depended on the availability of precursors for their expansion by macromolecular synthesis. 
Experimental results and logical deductions support the hypothesis that the earliest forms of life relied on RNA 
molecules to perform replication and other catalysis1–3. Initially, life may have evolved within confined inor-
ganic cavities that were possibly located in mineral precipitates such as of iron monosulphide2 or on clay, which 
promotes encapsulation by lipids4. It is not clear how long the period of RNA dominance lasted before proteins 
took over most catalytic functions. But, primitive cells are believed to have evolved through several eras, which 
included the sequential introduction of functional RNAs, RNPs and proteins culminating in the last universal 
common ancestor (LUCA), which existed prior to the divergence of the domains of Bacteria, Archaea, and finally 
the appearance of Eukarya2,5. These primitive forms are presumed to have faced the same challenge, as do modern 
cells, which is to selectively concentrate the precursor molecules required for cell replication and function. The 
proposed membrane composition of the very early evolving cells, believed to consist of a mixture of fatty acids, 
glycerol esters and amphiphiles, is more permeable than a membrane of homogeneous lipid composition6–8. 
Small hydrophilic molecules might also have been flipped into the primitive cell by association with charged 
head-groups of the early membrane constituents9. However, neither diffusion nor flipping provides much selec-
tivity to the distribution of small molecules that enter the cell and would have limited the rate of RNA replication 
in these primitive cells. Once cell membranes evolved to include hydrocarbon chains and ether/ester bonds on a 
glycerophosphate backbone, the permeability to hydrophilic molecules would have decreased and the cells then 
needed to evolve transporters to efficiently move needed metabolic precursors into the cell10.
Aptamers are small nucleic acids with high affinities and specificities for a particular target molecule or a group 
of related molecules. They can be obtained in vitro by repeated selection and amplification of nucleic acid popu-
lations that bind a chosen molecular target11–14. Aptamer-like activities are also found as the recognition elements 
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in riboswitches, which are portions of RNAs that regulate transcription or translation differently when unbound 
compared with when bound to their target ligand. These RNA elements may date back to a period prior to the 
divergence of the Bacteria and Archaea domains. This is suggested by the sequence of the TPP riboswitch which is 
closely related in eubacteria and archaebacteria15. Here we consider that aptamers may have been “transporters” 
of RNA precursors during the earlier era of RNA predominance and later once a primitive membrane had evolved 
such as in LUCA. As the cellular metabolism and architecture became more complex, aptamers would have also 
evolved into components of modern-day riboswitches by which they regulate transcription and translation.
We show, experimentally and by mathematical modeling, that RNA aptamers present inside a cell are capable 
of increasing both the total amounts and the free intracellular concentrations of the small molecules to which they 
bind. A previous mathematical model based on partial differential equations (PDE), by which we predicted this 
effect, required that the intracellular aptamer be mobile16. Here we describe a related compartmental model in 
which mobile aptamers have access to their small molecule ligands located near the surface of the inner cell mem-
brane (Math Model, Supplementary Information). By capturing and moving their ligands from the cell mem-
brane where they could readily exit the cell, the aptamers drive the intracellular free ligand concentrations up.
With the development of the cell membrane, a primitive cell would have been advantaged by the ability of 
aptamers to capture and accumulate substrates for continued replication. The capability of selectively retaining 
the appropriate small molecule precursors and making them available to the replicating RNA or DNA would 
have given an evolutionary advantage over other cells. Curiously, many of the identified riboswitches recognize 
molecules chemically related to nucleic acid precursors.
As well as their proposed existence during early evolution, the ability of aptamers to behave as DRAGINs 
might be applied in current biology in such contexts as building the minimal cell in vitro or to clinical applica-
tions such as to enhance the effectiveness of drugs with intracellular targets. In light of their ability to increase the 
intracellular free concentrations of small molecules, such as drugs, we have dubbed these intracellularly expressed 
aptamers as DRAGINs (Drug Binding Aptamers for Growing Intracellular Numbers).
Materials and Methods
Reagents. Aminoglycosides, neomycin-B, kanamycin-A and Geneticin (G418), were purchased as their sul-
fate salts from Sigma-Aldrich (St. Louis, MO). Bacterial and yeast expression vectors and their expected expressed 
RNA products are listed in Tables S1–S3.
Cell Growth Analysis. BL21 (DE3) star E. coli (Invitrogen, Eugene, OR) were transformed with the identi-
fied bacterial expression vectors and grown for 18 h at 37 °C in Luria-Bertani broth (LB) with 100 μg/mL ampi-
cillin. The cultures were then diluted 100 times and grown at 37 °C to OD = 1.0. The cells were again diluted 100 
times (or as identified for the experiment) in LB and grown for 1 h with 1 mM IPTG at 37 °C. Aminoglycosides 
were added according to the experimental protocol and the cells were grown for 12 h at 37 °C in a Biotek Synergy 
plate reader sealed with Breathe-Easy sealing membrane (Research Products International Corp). To obtain 
growth curves, the OD600 was taken every 5, 20 or 60 min, depending on the experiment.
Saccharomyces cerevisiae BY4735 were transformed with the identified yeast expression vectors as previously 
described17. The transformed cells were grown in SD-Uracil media in presence of 2% of glucose or raffinose for 
19 h at 30 °C. Cells were diluted to A600 = 0.2 and Geneticin (G418) was added and grown in SD-Uracil media with 
2% glucose or 2% galactose, 1% raffinose in Biotek Synergy plate reader for 30 h at 30 °C. Absorption at 600 nm 
(A600) was determined every 1 h for up to 30 h.
Northern Blot Analysis. The small RNA subfraction was extracted from E. coli using a small RNA puri-
fication kit (Sureprep Small RNA purification kit, Fisher Bio reagents) according to the manufacturer’s instruc-
tions. The RNA was resolved by electrophoresis through an 8% urea-polyacrylamide gel in TBE buffer (0.1 M 
Tris, 0.1 M Borate, 1 mM EDTA, pH 9), blotted to a nylon membrane (Zeta probe GT genomic tested blotting 
membrane) in TBE buffer at 10 V (room temperature for 1 h). The membrane was UV-cross-linked (120 mJ/cm2, 
UV Stratalinker, Stratagene). 32P-labeled oligonucleotides with sequences complementary to the control RNA, 
NEO1A or NEO4A aptamers were used as probes. The northern blot protocol is described in more detail in 
Supplementary Information.
Results
Aptamers increase intracellular total drug concentration. To test the hypothesis that mobile aptam-
ers inside a cell could increase the intracellular concentration of a small molecule ligand for which the membrane 
restricts entry16 we used NEO1A, a neomycin-B binding aptamer18, and paromomycin labeled with Cy3 as its 
ligand19. The affinity of NEO1A for Cy3-paromomycin was determined by isothermal titration calorimetry (ITC) 
to be 3.6 ± 0.4 μM when tested in a buffer that approximates the intracellular salt concentrations of mammalian 
cells19. E. coli expressing the neomycin-B aptamer accumulated Cy3-paromomycin to significantly higher levels 
than when the same cells expressed a control RNA (Figs 1 and S1–3). Expression of the control and aptamer 
RNAs were confirmed by northern blot analysis. Cy3 was not accumulated by cells when supplied alone or in 
combination with paromomycin. These results show that cells expressing aptamers accumulate more ligand than 
without aptamer expression, but the form of the ligand, e.g. bound to aptamer or free, in the cytosol cannot be 
distinguished.
Aptamers increase intracellular free drug concentration. The previous mathematical model pre-
dicted that mobile aptamers in the cell will act as DRAGINs and increase the intracellular concentration of the 
free form of the aptamer ligand. The DRAGIN effect described by the model is due to the aptamer competing for 
ligand export through the cell membrane and establishing a semi-equilibrium within the cytoplasm that increases 
the intracellular concentration of the free form of the ligand. Although it is consistent with this prediction, the 
www.nature.com/scientificreports/
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observed increase in total aptamer ligand could also be accomplished by the aptamer providing additional hold-
ing capacity for its ligand, which should lower the intracellular concentration of the free ligand form16.
To determine if the intracellular free aminoglycoside concentrations could be raised by the expression of 
aptamers, we tested the ability of aminoglycosides to kill E. coli that expressed aminoglycoside aptamers com-
pared with control RNA. If the aptamers were capable of behaving as DRAGINS by increasing the intracellular 
free ligand concentration, cells expressing aptamers would be killed more effectively than cells expressing con-
trol RNAs. However, if the expressed aptamers sequestered the aminoglycosides by increasing holding capacity, 
the cells were expected to be protected from killing. Consistent with the proposed DRAGIN activity, cells that 
expressed aptamers grew more slowly in the presence of the same aminoglycoside concentration compared to 
cells that expressed control RNAs (Fig. 2). This result was demonstrated with several combinations of aptamers 
and aminoglycosides in bacteria (Figs 2A and S4–S7) and yeast (Fig. 2B). The impact of aptamer expression was to 
decrease the effective concentration of aminoglycoside required to kill the cells (IC50) by 2-3-fold (Fig. 2C). These 
results were confirmed by minimal inhibitory concentration (MIC) analysis (Fig. S8, Tables S4 and S5). Northern 
blots of RNA isolated from E. coli that carried either the control RNA expression plasmid or the aptamer expres-
sion plasmids verified that RNAs containing the aptamers were expressed and present in the latter cells and not in 
the former (Fig. 2D), whereas the control RNA was expressed in the former (Fig. S9).
A compartment model for the effect of aptamer expression on ligand accumulation in cells. 
To evaluate the mechanism by which aptamers increase intracellular ligand concentrations, we turned to a math-
ematical model. Our previous PDE-based model was replaced with a simplified ordinary differential equation 
(ODE)-based compartment model (Math Model, Supplementary Information) in which the ribosomes (R), which 
are the targets of the aminoglycosides, are the proxy for the cells and their proliferation. The model includes five 
compartments, which are the i) e, cell exterior, ii) m, outer cell membrane and the periplasmic space, iii) cf, inner 
cell membrane, iv) j, cytoplasmic juxtamembrane space and v) c, remainder of the cytoplasm (Fig. 3A). Ligand 
concentrations are computed for the cytoplasm, the inner cell membrane and the cell exterior by numerical solu-
tions of the system of ODEs described in the Math Model (Supplementary Information). There are no dynamical 
equations for the concentrations of the chemical species in the juxtamembrane compartment and the region 
between the inner membrane and the exterior because those concentrations are related to their counterparts in 
the ODE regions by the partition coefficients.
Molecular diffusion was a parameter in the PDE model16. Entities, such as the ribosome, with relatively low 
diffusion rates would less frequently encounter the inner membrane surface compared with the smaller more 
rapidly moving aptamers. In the compartment model, the juxtamembrane space, which is considered to be a thin 
zone immediately adjacent to the inner membrane surface, is a surrogate for the consequence of a combination 
of molecular mobility and folded molecular shape and size, which will influence the frequency that a particular 
molecule will access the inner membrane surface with sufficient intimacy to pick up a ligand molecule. Due to 
Figure 1. Aptamer expression increases the intracellular concentration of its ligand. E. coli BL21 cells 
expressing control RNA (blue bars) or the neomycin-B aptamer, NEO1A (red bars), were grown for three 
hours in the presence of either 7 μM Cy3, 7 μM Cy3 and 7 μM paromomycin, or 7 μM Cy3-paromomycin, then 
collected and read by fluorescence spectroscopy with λex = 510 nm λem = 563 nm. The fluorescence for each 
condition was determined immediately after adding the fluorophores for the 0-time control. This value was 
subtracted from the fluorescence for the same condition that was obtained after 3 h incubation to obtain the 
results shown. This result represents a single experiment that was performed in triplicate and is supported by 
similar results from 7 other independently performed experiments (Figs S1–S3).
www.nature.com/scientificreports/
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their large size, the ribosome targets of the aminoglycosides are considered to reside in the cytosol with no access 
to the juxtamembrane space. The smaller aptamers can populate both the cytoplasm and the juxtamembrane 
space. Drug exporters are present in the membrane/cell wall compartment, and the aminoglycoside ligand is 
initially added as a bolus to the extracellular space. Because the extracellular volume is very large compared to the 
cell volume, the extracellular concentration of aminoglycoside is considered a constant.
As did the PDE model, this model predicted that the presence of aminoglycoside-binding aptamers in the 
cytoplasm would increase the intracellular free aminoglycoside concentration and thereby decrease the extra-
cellular concentration of aminoglycoside required to kill the cells (Fig. 2E), which was what we observed exper-
imentally (Fig. 2A–C). When tested over a range of affinities for aminoglycosides of ribosomes and aptamers, 
the model predicts a “sweet spot” of combinations of affinities of the aptamer and the ligand target (here the 
ribosome) in which the experimentally observed DRAGIN activity can occur (Fig. 3). The model predicted that 
the DRAGIN effect requires access of the aptamer to the juxtamembrane space (cf. Fig. 3B,C). It also showed that 
aptamers with relatively low ligand affinities (Kds in the micromolar to millimolar range) were effective DRAGINS 
and increased the intracellular concentration of free ligand. Aptamers with very high affinities were predicted to 
protect the cells due to the aptamer:ligand equilibrium being shifted more towards the aptamer-ligand complex 
(cf. Fig. 3B,C).
The DRAGIN effect is dictated by the specificity of the aptamer. If the DRAGIN effect is due to the 
aptamer interacting with its ligand then it should reflect the ligand specificity of the expressed aptamer. We tested 
this question with the NEO1A aptamer expressed in cells that were grown in the presence of neomycin-B (Fig. 4A) 
or tetracycline (Fig. 4B). The expression of NEO1A sensitized the cells to the cognate ligand, neomycin-B, but not 
to the orthologous ligand, tetracycline. The affinity of NEO1A for tetracycline was so low as to be unmeasurable 
by ITC (Fig. S10). These results demonstrate that the DRAGINs activity is a function of the specificity of the 
Figure 2. The NEO1A aptamer increases the effectiveness of its ligand in killing cells. (A) BL21 cells expressing 
control RNA or the neomycin-B aptamer, NEO1A, were grown for 8 h after the addition of 1 mM IPTG with 
their density determined each hour. Error bars are the standard deviations of triplicates. (B,C) Aptamer 
expression decreases the IC50 for cell growth in yeast and bacteria: (B) Saccharomyces cerevisiae (strain BY4735) 
expressing control RNA (the Spinach aptamer) or NEO1A were grown in SD-Uracil medium with 2% glucose in 
the presence of various concentrations of G418 and their normalized growth rates were plotted against the G418 
concentration. Error bars are equal to 1 minus the coefficient of determination of the regression line for each 
determined slope. Error bars are associated with each point, but not observed when they are smaller than the 
height of the symbol. (C) E. coli expressing control RNA or the NEO1A were grown in triplicate in the presence 
of various concentrations of neomycin-B and cell densities after 1 h were plotted against the neomycin-B 
concentration with the standard deviations as error bars. This data is representative of three experiments from 
which similar results were obtained. (D) Northern blots of RNA isolated from cells that were induced or not 
induced by IPTG to produce the NEO1A aptamers for an incubation period of 1 h in the presence of 1 mM 
IPTG. (E) Cellular growth curves predicted by the math model for controls (no aptamer) and cells that produce 
aptamer at two different rates (λ = 5 and 10), all in the presence of 5 μM inhibitor. This is Fig. 1a in the Math 
Model (Supplementary Information).
www.nature.com/scientificreports/
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aptamer expressed by the cells and not due to a nonspecific effect caused by the plasmid presence or IPTG-driven 
RNA expression. In other experiments, IPTG induction was found to have some effect on the growth rate, par-
ticularly at lower inoculum densities (Fig. S11). However, with the same inoculum density and IPTG concentra-
tions, there was no significant difference between the growth rates of cells transformed by expression vectors for 
the control RNA or the aptamers (Fig. S12).
Aptamers without DRAGIN activity. The compartment model predicted that aptamers with high affini-
ties (Kd < 10−7 M) would decrease the intracellular concentration of free ligand and protect the cells from killing 
by a toxic ligand, whereas aptamers with affinities in the “sweet spot” (Kds between 10−3 and 10−5 M) would 
increase cell killing (Fig. 5A). Although the intracellular Kds for these aptamers in the context of the expressed 
RNAs are not known, the Kds measured in vitro for these aminoglycoside aptamers are between these two optima. 
We tested the effect of two neomycin-B aptamers with different affinities for aminoglycosides. The higher affin-
ity aptamer, NEO4A, binds neomycin-B with a Kd of 99 nM, whereas the lower affinity aptamer, NEO1A, binds 
neomycin-B with a Kd of 292 nM (Table S5). Consistent with the model prediction, expression of the higher affin-
ity aptamer (NEO4A) frequently protected cells in which it was expressed from killing by neomycin-B. By con-
trast, expression of the lower affinity aptamer (NEO1A) promoted killing and never protected cells from killing by 
neomycin-B of the cells in which it was expressed (Fig. 5B). However, the difference in affinities for neomycin-B of 
NEO1A and NEO4A was only three-fold when measured in vitro. With the math model predicting a large affinity 
range between the optimum for protection vs. killing, it seemed unlikely that this small difference in affinities of 
these two aptamers would be sufficient to switch an aptamer from a DRAGIN that promotes killing to one that 
reduces the free intracellular ligand concentration, presumably by sequestering the ligand, to promote protection.
We further investigated the data for NEO1A and NEO4A to establish if the difference between the effects of 
these two aptamers on killing by neomycin-B is statistically significant. Of a total of 51 independent experiments 
Figure 3. A compartmental model for the effect of expressed aptamers on cell growth. (A) The model (see the 
Math Model (Supplementary Information) for a full mathematical discussion) includes five compartments: 
(1) cytosol, (2) juxtamembrane space, (3) inner membrane, (4) periplasmic space and outer membrane and 
(5) cell exterior. The ribosome (R) is the target of the aminoglycosides used in this study. The ribosome (R) to 
cell ratio is assumed as constant and the ribosome concentration is used as a surrogate for cell density. R has 
access to the cytosol, but not the juxtamembrane compartment. The aptamers (A) expressed by the cells can 
access both cytosol and juxtamembrane compartment. Pumps capable of exporting the aptamer ligand extend 
from the inner membrane to the cell exterior. The aptamer ligand (I) is sourced in the extracellular space 
and is maintained at a constant level. (B) Model prediction when the aptamer has high permeability into the 
juxtamembrane compartment (Fig. 5D, Mathematical model, Supplementary Material). The relation between 
ribosome affinity and aptamer affinities, expressed as −log(KdR:I) and −log (KdA:I), and the cell density after one 
hour, expressed as fraction of control (no ligand/inhibitor). The Kds for both aptamer and ribosome were varied 
by changing the off-rate (k−1). (C) Model prediction when aptamer has low permeability to the juxtamembrane 
compartment (Math Model, Supplementary Information). The numerical values used to generate (B,C) are found 
in Supplementary Information (Fig. 5A, Math Model, Table 1 or in the caption for Fig. 5).
www.nature.com/scientificreports/
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performed by 5 people (independent operators), NEO1A never promoted protection of the cells in which it 
was expressed, whereas it promoted killing by neomycin-B in 88% (45) of these experiments (Fig. 5C). In some 
instances, several ligands were compared in the same experiments for the effect of aptamer expression on killing 
compared with control RNA expressed by a parallel cell culture. In total, of 114 separate tests of the effect of 
NEO1A expression (as a singlemer or multimer) on killing by a variety of ligands, NEO1A mostly promoted 
killing (70%) and protection against killing was not observed with any of the aminoglycoside ligands. By contrast, 
the distribution of effects on killing due to the expression of NEO4A was quite different: Of 23 independently per-
formed experiments by 3 people, only 6 showed the promotion of killing and 10 promoted protection (Fig. 5C). 
For all ligands the numbers for NEO4A expression were kills (6), no effect (7) and protects (15). Statistical anal-
ysis of the data represented in Fig. 5C using Fisher’s exact test for independence of the distribution between the 
three effects (kill, no effect, protection) for the two aptamers yielded a p value of 3.4 × 10−8, which rejects the null 
hypothesis and supports our conclusion that NEO1A promotes killing and NEO4A tends to promote protection. 
The variable protective response of NEO4A could be due to this aptamer not having quite a high enough affinity 
for the ligand to always protect or not always being expressed at high enough levels to achieve protection.
To further test if the function (protection or killing) of these aptamers is due to their affinities for their ligands, 
we tested the ability of the NEO1A and NEO4A aptamers to protect from or enhance cell killing by a ligand for 
which both had much lower affinity than for neomycin-B. Kanamycin-A, has affinities for NEO1A and NEO4A 
of 43 and 11 µM respectively. Similar to the results for neomycin-B, NEO4A protected the cells from killing by 
kanamycin-A in two of two experiments, whereas NEO1A promoted cell killing by kanamycin-A in all 14 experi-
ments in which it was tested (Fig. 5D). Thus, although the relative affinities of the aptamers for kanamycin-A were 
the same as for neomycin-B, with NEO4A having the higher affinity in each case, it is unlikely that the relative 
ligand affinities of these aptamers are primarily responsible for the DRAGIN or protection effects on cell growth 
rate. This suggests that another parameter must be important in determining the effect of a particular aptamer on 
the intracellular concentration of its ligand in the cells in which it is expressed.
Impact of access to the juxtamembrane space for DRAGIN activity. To investigate other possible 
contributors to the killing or protective activity of aminoglycoside aptamers expressed in cells, we first modeled 
the effect of changing the level of expression of the aptamer. At higher concentrations in the cell, we speculated 
that the aptamer might become a “sponge” for the ligand. However, the model showed that increasing the source 
rate of an aptamer that promotes killing increased the killing activity and did not result in protection from killing 
by the ligand (Fig. 6A). The highest aptamer concentrations tested in the model were 20 times the concentration 
of ribosomes. This concentration is much higher than can be expected for an expressed RNA even from a plasmid 
in bacteria in which the ribosomes are present at about 104 per cell20 and all other RNAs combined are present at 
about 1-2 × 103 per cell21.
We evaluated the impact of access to the juxtamembrane compartment. The original PDE model clearly 
demonstrated that mobility of the aptamer is required for aptamers to increase the intracellular free concentra-
tion of drug16. The compartment model mimics the original model by including a juxtamembrane compartment 
that the aptamer can populate, but that is not accessible to larger molecules such as the ribosome target of the 
aptamer ligand (Fig. 3B, Math Model, Supplementary Information). Without access to the juxtamembrane space, 
the aptamer cannot increase the intracellular concentration of its ligand and promote killing (Figs 3B and 5B). 
Figure 4. Specificity of the DRAGINs effect for the cognate ligand. BL21 cells expressing the control RNA or 
the NEO1A aptamer were incubated with various concentrations of neomycin-B (A) or tetracycline (B) and 
cultured for 12 h. The maximum growth rates were determined, normalized to the rate for the same cell culture 
in the absence of drug and plotted as a function of drug concentration. Errors (1-coefficient of determination) 
for the regression analysis were all smaller than the sizes of the symbols.
www.nature.com/scientificreports/
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Thus, DRAGIN activity might not be observed with an aptamer that is linked to a larger molecule that would be 
less mobile and have less direct access to the internal membrane surface. We tested this hypothesis using strings of 
five and seven tobramycin aptamers (TOB3A) that have been previously demonstrated to bind their tobramycin 
ligands in vivo17,19. The string of five tandem tobramycin aptamers binds tobramycin with a range of Kds between 
4.3 and 46 μM compared with the 240 nM Kd estimated for the singlemer TOB3A aptamer19. According to the 
model, if affinity plays a predominant role in determining the DRAGIN effect of these aptamers, both singlemer 
TOB3A and tandemers of 5 or more TOB3A aptamers should either promote cell killing or not have any effect 
on cell survival. However, singlemers and tandemers differ in size and shape, which could limit molecular access 
to the inner membrane surface (juxtamembrane space in the model, Math Model, Supplementary Information). 
Indeed we observed that strings of five and seven TOB3A tandem aptamers protected the cells from killing, while 
the TOB3A singlemer promoted cell killing by tobramycin (Fig. 6C). The reason for this difference in the effect 
of singlemer and tandemers on drug efficacy is unlikely to be simply due to the different number of aptamers in 
tandem in each RNA or the sizes of the RNAs because other data with different aptamers and ligands show the 
DRAGIN effect with singlemers, 2mers and 3mers (Figs S4–S7). Mobility is a function of the distance cubed 
and is unlikely to be sufficiently different for the singlemer and 5-tandemer to have contributed to the observed 
Figure 5. Comparison of two aptamers with different propensities to protect or kill the cells in which they are 
expressed. (A) The math model predictions for the effect on growth rate of cells expressing high affinity (green) 
or low affinity (red) aptamers (Math Model, Supplementary Information, Fig. 2B). The numerical values used to 
generate (A) are in the Supplementary Information (Math Model, Table 1 and the caption for Fig. 2). (B) BL21 
cells expressing control RNA, the low affinity NEO1A, or the higher affinity neomycin-B aptamer, NEO4A, 
were grown in the presence of various concentrations of neomycin-B after induction with 1 mM IPTG. Growth 
rates were normalized to the initial cell density in each data set. Error bars are smaller than the symbol size. 
(C) The percent of experiments showing killing, protection or no effect by neomycin-B for cells expressing 
NEO1A and NEO4A compared with cells expressing the control RNA. The numbers over the bars identify the 
number of independent experiments. (D) BL21 cells expressing control RNA, NEO1A, or NEO4A, were grown 
in the presence of various concentrations of kanamycin-A after induction with 1 mM IPTG. Growth rates were 
normalized to the initial cell density in each data set. The plot shows an average of the data from 4 experiments, 
each performed in triplicate.
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effects. We speculate that the most probable explanation for these results is that the multi-aptamer tobramycin 
RNAs form 3D structures that limit their access to the juxtamembrane space, with the result that they are inef-
fective as DRAGINs and effective in protection because they can still bind and sequester some of the ligand that 
makes its way into the cytosol.
Discussion
We have shown that intracellular receptors, such as aptamers, can behave as DRAGINs to influence accumulation 
in the cell of the small molecule(s) that they selectively recognize. The outcome is an increase in the intracellular 
concentration of the free form of the small molecule ligand when the aptamer is present in the cytosol. The pre-
vious PDE-based mathematical model predicted that the DRAGIN activity would be observed for aptamers with 
affinities for their ligands in a certain range, which encompasses the affinities reported for most aptamers16. With 
the compartmental model we show that, at sufficiently high levels of expression, aptamers with high affinities 
could protect the cells by capturing and retaining the incoming ligand. Here and in a previous report22, some 
aptamers were found to protect the cells in which they were expressed from killing by their drug ligand. In our 
studies, a comparison of the effects of NEO1A and NEO4A that bind neomycin-B with different affinities showed 
that the lower affinity NEO1A reliably demonstrated DRAGIN activity, whereas the higher affinity NEO4A 
aptamer had a significant tendency towards cell protection. However, these same tendencies were demonstrated 
for NEO1A and NEO4A with the ligand kanamycin-A for which both have lower affinities than for neomycin-B. 
We also showed that RNA size cannot be correlated with demonstrated DRAGIN activity and speculate that the 
3D folding of the RNAs containing the aptamer sequences might be a critical feature for determining if an intra-
cellularly expressed aptamer is a DRAGIN. Consistent with this postulate, we have found that, whereas NEO4A 
protects cells when expressed from a Trc promoter, it has no effect when expressed from T7 promoter, which is 
also regulated by LacO. Northern blots showed that RNAs of different sizes were produced from these promoters, 
which might fold differently in the cytosol (Fig. S9).
The current compartment model and the previous PDE model16 included features that allowed access of the 
aptamers to the inner surface of the cell membrane. Intimate membrane access was allowed in the PDE model 
by aptamer mobility and in the ODE compartment model by access to the juxtamembrane compartment. Thus, 
we speculate that an important property of a DRAGIN aptamer is its ability to intimately access the inner surface 
of the membrane and pick off aminoglycosides hovering at the inner membrane face that would otherwise be 
removed by diffusion through the membrane or by export enabled by drug pumps. For example, an aptamer 
may be more likely to be a DRAGIN if the ligand binding pocket can closely approach the inner surface of the 
membrane. Our observations that the TOB3A aptamer is a DRAGIN as a singlemer and protects as a tandemer 
and that the NEO4A aptamer DRAGIN properties depend on its RNA sequence context are consistent with the 
possibility that RNA structure might play a role in determining if an aptamer can perform as a DRAGIN. It is also 
likely that features of the drug will be important for enabling DRAGIN activity. For example, aminoglycosides are 
positively charged and so might hover for a longer time on the inner membrane surface than would a drug that is 
hydrophobic or not positively charged. This longer dwell time may provide more opportunity for an aptamer to 
pick off its ligand and transport it into the cytosol.
An important insight from these studies is that aptamers with DRAGIN activity can increase the available 
intracellular concentrations of their ligands. Thus, DRAGIN aptamers might provide a means of expanding drug 
treatments to some currently unreachable drug targets. In this vein, another means of breaking the undruggable 
barrier was identified with the previous PDE model by which it was demonstrated that, if the target enzyme was 
made mobile, it performed the same DRAGIN function as the aptamer16. However, as for aptamers, protein struc-
ture and the location of the drug binding site on the protein target along with chemical properties of the drug may 
play a role in enabling capture of the drug in the juxtamembrane region.
Figure 6. Tobramycin aptamers enhance lethality as singlemers and protect from killing when in tandem 
arrays. (A) The expression level of aptamers (Kd = 10−4 M) is varied in the compartment model (Fig. 3A, Math 
Model, Supplementary Information). (B) Access to the juxtamembrane compartment is severely restricted 
in the compartment model (Fig. 6B, Math Model, Supplementary Information). The numerical values used 
to generate. (A,B) are to be found in the Supplementary Information (Math Model, Table 1 and the captions 
for Figs 3 and 6). (C) Cells expressing control RNA, singlemers, and tandemers of five and seven tobramycin 
aptamers were tested for their growth rates in the absence or presence of tobramycin from 2.5 to 7.5 μM. Errors 
(1-coefficients of determination) are smaller than the symbol sizes.
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RNAs are proposed to have performed the work of replication in primitive cells prior to the advent of pro-
teins. Early life is proposed to have first consisted of RNA polymers capable of replication, which may have first 
been created under conditions of repeated concentration due to cycles of drying and rehydration that promoted 
polymerization over hydrolysis23. Eventually these polymers became surrounded by a membrane, which first 
may have consisted of ethers and fatty acids and later evolved to consist of phospholipids or glycerophosphate 
ethers after the split of the Bacteria and Archaea domains2. The hydrophobic primitive membrane would have 
been a barrier for precursors of RNA synthesis. Although precursor entry can be enabled by flipping of individ-
ual lipid components of the membrane, a primitive cell would have been advantaged for evolution if it were able 
to more rapidly and selectively capture and concentrate precursors for RNA synthesis. Our results suggest that 
RNA aptamers could have performed this function by selectively picking off the appropriate precursors from the 
primitive membrane and moving them away from the inner membrane surface from which they might otherwise 
have been flipped again to the outside. In this regard, it is of interest that a relatively large percentage of known 
riboswitches (9 of 20) recognize molecules structurally related to nucleosides. Comparison of the TPP riboswitch 
sequences in eubacteria and archaebacteria resulted in this riboswitch being described as a “molecular fossil” with 
an evolutionary origin that predates the appearance of proteins and the transcriptional and translational events 
that it regulates in modern cells15. Considering that central metabolism of modern cells is driven by the intracel-
lular concentrations of small molecules that are brought in from the extracellular environment, some RNAs in 
modern cells may contain aptamer-like domains with DRAGIN activities that influence the accumulation and 
availability of certain nutrients brought in by membrane-localized protein transporters.
In our studies we have used RNA aptamers as the intracellular receptors to shift the distribution of their lig-
ands into the cell. However, the math model does not define the molecular entity. Thus, small mobile proteins, 
or other polymers with specificity for an identified target drug, might also perform the DRAGIN function. The 
development of molecules with a DRAGIN function might have several modern-day applications. In addition 
to improving chemotherapeutics to reach currently undruggable targets, another potential area of application of 
DRAGINs is in synthetic biology to promote the intracellular accumulation of selected small molecules. Microbes 
might be developed that express DRAGINs for environmental toxins to promote their intracellular accumulation 
for environmental cleansing. Aptamers expressed from specific gene promoters could also be used to image cells 
with radiolabeled nontoxic aptamer ligands.
In summary, our results demonstrate that small RNA aptamers can selectively increase the intracellular free 
concentrations of their respective ligands. Mathematical modeling identified ligand affinity as one parameter that 
determines DRAGIN activity, but with the limited range of aptamer affinities available for study, experimentation 
found little correlation of ligand affinity with DRAGIN activity. This suggests that other features are also required 
in the model of which we speculate that the most important is the ability of the aptamer to closely approach the 
intracellular surface of the plasma membrane, which likely depends on RNA structure. Although RNA structure 
cannot be incorporated into a compartment model, accessibility of the ligand binding site for the inner mem-
brane can be modeled by altering access to the juxtamembrane space. This proxy for RNA structure produced 
results from the model consistent with the hypothesis that RNA structure might be an important parameter that 
determines DRAGIN activity. Our findings support a feasible hypothesis to explain the means by which primi-
tive cells might have concentrated synthetic precursors. The concept that intracellular entities can influence the 
intracellular accumulation of small molecules coming from the outside adds a new dimension to understanding 
how cellular metabolism might be driven and how the concentrations of drugs, toxins and energy sources could 
be altered in cells.
Data Availability
All data discussed in this report is available from the authors on request.
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